CD274 and cancer: Recent advances in immunotherapy have led to the development of immune-checkpoint inhibitors (ICIs), which have shown promising results in the treatment of various cancers, including PDAC [82] ICIs work by blocking the interaction between immune-checkpoint proteins (e.g., PD-L1) and their receptors on T cells, thereby releasing the immune system’s brakes and allowing it to attack cancer cells.